Glaucoma

Table of Contents

1. What Glaucoma Is
2. Types of Glaucoma
3. Risk Factors
4. Symptoms and Early Detection
5. Conventional Treatments
6. Natural Approaches
7. Lifestyle Modifications
8. Foods Studied for Eye Health
9. Foods Linked to Higher Eye Pressure or Glaucoma Risk
10. Eye Pressure Monitoring
11. Cautions and Considerations
12. Key Research Papers
13. Featured Videos

1. What Glaucoma Is

Glaucoma is a group of eye conditions that damage the optic nerve, which is essential for transmitting visual information from the eye to the brain. The damage is most often caused by abnormally high intraocular pressure (IOP), though glaucoma can also occur at normal pressure levels. Left untreated, glaucoma leads to progressive, irreversible vision loss and is one of the leading causes of blindness worldwide.

From a naturopathic perspective, glaucoma is understood not simply as an isolated eye condition but as a reflection of broader systemic imbalances, including poor circulation, oxidative stress, and nutrient deficiencies. A whole-body approach that supports vascular health, reduces inflammation, and nourishes the optic nerve can complement conventional treatment strategies.

2. Types of Glaucoma

Open-Angle Glaucoma

• Most common form, accounting for approximately 90% of cases.
• The drainage angle between the iris and cornea remains open, but the trabecular meshwork becomes partially blocked over time.
• Develops gradually with no early warning signs; peripheral vision is lost slowly.
• Often called the "silent thief of sight" because damage occurs before symptoms are noticed.

Angle-Closure Glaucoma

• Less common but more acute; can be a medical emergency.
• The iris bulges forward, physically blocking the drainage angle and causing a sudden spike in intraocular pressure.
• Symptoms include severe eye pain, headache, nausea, halos around lights, and sudden blurred vision.
• Treated as an emergency because vision can be lost rapidly.

Normal-Tension Glaucoma

• Optic nerve damage occurs despite intraocular pressure being within the normal range.
• May be related to poor blood flow to the optic nerve or heightened nerve sensitivity.
• Naturopathic approaches for this type focus on circulation.

3. Risk Factors

• Age: Risk increases significantly after age 60.
• Family history: Having a first-degree relative with glaucoma greatly increases risk.
• Ethnicity: Higher prevalence in African American, Hispanic, and Asian populations.
• Elevated intraocular pressure: The most significant modifiable risk factor.
• Myopia (nearsightedness): Associated with open-angle glaucoma.
• Diabetes: Impaired microvascular health may contribute to optic nerve damage.
• Corticosteroid use: Prolonged use of steroid eye drops or systemic steroids can raise IOP.
• Eye injuries or surgeries: Prior trauma can compromise drainage structures.
• Low blood pressure: May reduce perfusion to the optic nerve, especially during sleep.

4. Symptoms and Early Detection

Open-angle glaucoma typically produces no noticeable symptoms in its early stages. Vision loss begins with peripheral (side) vision and progresses inward. Many people do not realize they have the condition until significant damage has occurred.

Warning signs of acute angle-closure glaucoma:

• Severe eye pain and headache
• Nausea and vomiting
• Blurred vision or halos around lights
• Redness of the eye
• Sudden visual disturbance, especially in low light

Early detection methods:

• Tonometry: Measures intraocular pressure.
• Ophthalmoscopy: Examines the optic nerve for signs of damage.
• Perimetry (visual field testing): Maps peripheral vision loss.
• Optical Coherence Tomography (OCT): Provides detailed images of the optic nerve fiber layer.
• Gonioscopy: Evaluates the drainage angle of the eye.

Regular comprehensive eye exams are the main way glaucoma is found early, especially after age 40, and early detection is the most effective way to preserve vision.

5. Conventional Treatments

• Prescription eye drops: Prostaglandin analogs (latanoprost), beta-blockers (timolol), alpha agonists, and carbonic anhydrase inhibitors reduce IOP by increasing fluid outflow or decreasing fluid production.
• Oral medications: Carbonic anhydrase inhibitors (acetazolamide) may be used when drops are insufficient.
• Laser therapy: Trabeculoplasty for open-angle glaucoma; iridotomy for angle-closure glaucoma. In the Laser in Glaucoma and Ocular Hypertension Trial (LiGHT), people with newly diagnosed open-angle glaucoma or high eye pressure were given either selective laser trabeculoplasty (SLT) or eye drops as their first treatment. A 6-year analysis of 710 eyes found side vision (visual field) was lost more slowly in the laser-first group (−0.26 decibels per year) than in the drops-first group (−0.37 decibels per year), with similar eye pressures during follow-up; the difference was clearest in mild glaucoma. The authors concluded that laser first was more effective than drops at preserving the visual field.
• Minimally invasive glaucoma surgery (MIGS): Newer procedures that improve fluid drainage with fewer complications.
• Traditional surgery: Trabeculectomy creates a new drainage pathway for aqueous humor.

Conventional treatments are effective at lowering IOP but do not reverse existing optic nerve damage. Natural approaches may support the overall health of the optic nerve and complement conventional care.

6. Natural Approaches

The following supplements and botanicals have been studied for their potential to support eye health in individuals with or at risk for glaucoma. They are studied as additions to, not replacements for, conventional treatment. The amounts listed below are those practitioners describe, unless a study is named.

Bilberry (Vaccinium myrtillus)

• Rich in anthocyanins that support microvascular integrity in the retina.
• May improve blood flow to the optic nerve and protect retinal ganglion cells.
• Amount practitioners describe: 160-320 mg standardized extract daily.

Ginkgo Biloba

• Enhances cerebral and ocular blood flow, and is studied particularly in normal-tension glaucoma.
• Contains flavonoids and terpenoids with antioxidant and neuroprotective properties.
• The main study is small: in a 2003 placebo-controlled crossover trial in 27 patients with normal-tension glaucoma (Quaranta et al.), visual field scores improved after 4 weeks of ginkgo extract (40 mg three times a day), with no change in eye pressure, blood pressure or heart rate. The authors concluded that ginkgo "appears to improve preexisting visual field damage in some patients".
• Amount practitioners describe: 120-240 mg standardized extract daily (the Quaranta study used 40 mg three times a day).

Magnesium

• Promotes vasodilation and improves blood flow to the optic nerve.
• May help reduce vasospasm, which is implicated in normal-tension glaucoma.
• Amount practitioners describe: 250-400 mg daily, usually as magnesium glycinate or citrate.

Coenzyme Q10 (CoQ10)

• A potent mitochondrial antioxidant that supports energy production in retinal ganglion cells.
• The suggestion that it may slow glaucomatous damage comes from laboratory and animal research; no human study of glaucoma progression is cited here.
• Amount practitioners describe: 100-300 mg daily.

Omega-3 Fatty Acids

• Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) from fish oil support anti-inflammatory pathways and healthy intraocular pressure regulation.
• May improve aqueous humor outflow.
• Amount practitioners describe: 1,000-2,000 mg combined eicosapentaenoic acid/docosahexaenoic acid daily.

Vitamin C

• High concentrations of vitamin C are found naturally in the aqueous humor of the eye.
• Has been shown in some studies to temporarily reduce intraocular pressure at high doses.
• Supports collagen integrity in the trabecular meshwork.
• Amount practitioners describe: 1,000-2,000 mg daily in divided doses.

Alpha-Lipoic Acid

• A versatile antioxidant that regenerates other antioxidants (vitamins C and E, glutathione).
• Crosses the blood-brain barrier, providing neuroprotection to the optic nerve.
• Amount practitioners describe: 150-300 mg daily.

Nicotinamide (Vitamin B3)

• Nicotinamide is a form of vitamin B3 that the body uses to make NAD+, a molecule cells need for energy. It is low in the blood of glaucoma patients and protects retinal ganglion cells in laboratory and animal models.
• In a 2020 Australian crossover trial, 57 people already treated for glaucoma took nicotinamide (1.5 g a day for 6 weeks, then 3.0 g a day for 6 weeks) or placebo. Inner-retina electrical function (measured by electroretinography) improved by 14.8% on nicotinamide and 5.2% on placebo, and there was a trend toward better visual fields.
• In a 2026 Korean crossover trial, 53 people with normal-tension glaucoma took nicotinamide (1 g a day for 6 weeks, then 2 g a day for 6 weeks) or placebo. Retinal electrical signals improved more on nicotinamide, but visual field scores did not change.
• A 2026 systematic review of eight human studies concluded that nicotinamide gives short-term effects on retinal function, that effects on the visual field were inconsistent, and that the evidence was "insufficient to establish sustained neuroprotection" or a change in glaucoma progression. Its authors wrote that larger, long-term trials are needed to settle the right dose, who benefits and long-term safety.

7. Lifestyle Modifications

Exercise

• Regular aerobic exercise (walking, cycling, swimming): a 2026 scoping review of 18 studies (4 of them randomized trials) found aerobic exercise consistently associated with short-term reductions in intraocular pressure and increases in blood flow pressure to the eye (ocular perfusion pressure). Observational studies linked more everyday physical activity with lower glaucoma rates and slower progression, though the review notes that cause and effect is not proven.
• Exercise improves overall blood flow, including perfusion to the optic nerve.
• General activity guidance often cited is at least 30 minutes of moderate activity, 5 days per week.
• Heavy weightlifting, inverted yoga positions, and high-intensity straining can spike IOP.

Stress Reduction

• Chronic stress increases cortisol, which may elevate intraocular pressure.
• Meditation, deep breathing, and progressive relaxation can help regulate the autonomic nervous system.
• Adequate sleep (7-8 hours) is important; sleeping with the head slightly elevated may reduce nocturnal IOP spikes.

Hydration

• Drinking a large amount of water at once can temporarily raise IOP; drinking steadily through the day is the pattern described as avoiding these spikes.
• Excessive caffeine may cause small, transient IOP increases.

8. Foods Studied for Eye Health

• Dark leafy greens (kale, spinach, collards): Rich in nitrates that improve blood flow and in lutein/zeaxanthin for retinal protection.
• Cold-water fatty fish (salmon, sardines, mackerel): Provide omega-3 fatty acids for anti-inflammatory support.
• Berries (blueberries, bilberries, blackberries): High in anthocyanins that support vascular health in the eye.
• Citrus fruits (oranges, grapefruits, lemons): Excellent sources of vitamin C.
• Nuts and seeds (almonds, walnuts, flaxseeds): Provide vitamin E, magnesium, and healthy fats.
• Colorful vegetables (bell peppers, carrots, sweet potatoes): Rich in carotenoids and antioxidants.
• Green tea: Contains catechins that may protect retinal cells from oxidative damage.
• Eggs: A bioavailable source of lutein and zeaxanthin.

9. Foods Linked to Higher Eye Pressure or Glaucoma Risk

• Excessive caffeine: May cause transient IOP elevations in some individuals.
• High-sodium foods: Can affect fluid balance and blood pressure regulation.
• Trans fats and highly processed foods: Promote systemic inflammation and oxidative stress.
• Excessive alcohol: Chronic heavy drinking is associated with increased glaucoma risk.
• Refined sugars: Contribute to insulin resistance and inflammation, which may impair ocular blood flow.
• Large fluid boluses: Drinking a large volume of any liquid in a short time can temporarily raise IOP.

10. Eye Pressure Monitoring

Consistent monitoring of intraocular pressure is a cornerstone of glaucoma management. Key considerations include:

• Regular eye exams: At minimum annually for those at risk; more frequently if diagnosed.
• Diurnal variation: IOP fluctuates throughout the day, often peaking in the early morning. Multiple readings at different times provide a more complete picture.
• Home tonometry: A home rebound tonometer allows patients to track their own IOP trends between clinic visits.
• Target pressure: Eye specialists set a target IOP for each patient that accounts for that person's risk profile and baseline nerve damage.
• Tracking lifestyle factors: Some patients keep a log of supplements, exercise, diet changes, and stress levels alongside IOP readings to see what influences their pressure.

11. Cautions and Considerations

• Stopping prescribed glaucoma medications removes their pressure-lowering effect. Uncontrolled IOP can cause rapid, irreversible vision loss.
• Ginkgo biloba may interact with blood-thinning medications (warfarin, aspirin); taken together, they may add to the risk of bleeding.
• High-dose vitamin C can cause gastrointestinal upset and may interfere with certain lab tests.
• Magnesium supplementation carries a risk of magnesium build-up in people with kidney disease, because the kidneys clear excess magnesium.
• Cannabis, though sometimes promoted for glaucoma, provides only short-lived IOP reduction and carries significant side effects.
• Supplements and prescriptions can interact; a full list of supplements lets each prescriber check for interactions.
• Acute angle-closure glaucoma is a medical emergency. Sudden severe eye pain with vision changes is a sign hospitals treat as urgent.

Key Research Papers

1. Kass MA, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Archives of Ophthalmology. 2002;120(6):701-713. — doi:10.1001/archopht.120.6.701
2. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. American Journal of Ophthalmology. 2000;130(4):429-440. — doi:10.1016/s0002-9394(00)00538-9
3. Heijl A, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Archives of Ophthalmology. 2002;120(10):1268-1279. — doi:10.1001/archopht.120.10.1268
4. Leske MC, et al. Predictors of long-term progression in the Early Manifest Glaucoma Trial. Ophthalmology. 2007;114(11):1965-1972. — doi:10.1016/j.ophtha.2007.03.016
5. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. British Journal of Ophthalmology. 2006;90(3):262-267. — Search PubMed
6. Weinreb RN, Khaw PT. Primary open-angle glaucoma. The Lancet. 2004;363(9422):1711-1720. — doi:10.1016/s0140-6736(04)16257-0
7. Quaranta L, et al. Effect of Ginkgo biloba extract on preexisting visual field damage in normal tension glaucoma. Ophthalmology. 2003;110(2):359-362. — doi:10.1016/s0161-6420(02)01745-1
8. Mozaffarieh M, Grieshaber MC, Flammer J. Oxygen and blood flow: players in the pathogenesis of glaucoma. Molecular Vision. 2008;14:224-233. — PubMed PMID: 18334938
9. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. American Journal of Ophthalmology. 1998;126(4):498-505. — doi:10.1016/s0002-9394(98)00272-4
10. Nucci C, et al. Neuroprotective agents in the management of glaucoma. Eye. 2018;32(5):938-945. — doi:10.1038/s41433-018-0050-2
11. Tham YC, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040. Ophthalmology. 2014;121(11):2081-2090. — doi:10.1016/j.ophtha.2014.05.013
12. Prum BE, et al. Primary open-angle glaucoma preferred practice pattern guidelines. Ophthalmology. 2016;123(1):P41-P111. — doi:10.1016/j.ophtha.2015.10.053
13. Montesano G, Crabb DP, Garway-Heath DF, Wright DM, Konstantakopoulou E, Nathwani N, Ometto G, Gazzard G. Six-year rate of visual field progression in the Laser in Glaucoma and Ocular Hypertension Trial. Ophthalmology. 2026;133(2):169-177. — PubMed PMID: 41043781
14. Hui F, Tang J, Williams PA, McGuinness MB, Hadoux X, Casson RJ, Coote M, Trounce IA, Martin KR, van Wijngaarden P, Crowston JG. Improvement in inner retinal function in glaucoma with nicotinamide (vitamin B3) supplementation: a crossover randomized clinical trial. Clinical & Experimental Ophthalmology. 2020;48(7):903-914. — PubMed PMID: 32721104
15. Ha A, Kim YK, Lee CK, Williams PA, Morgan JE, Shin YI, Kim E, Kim M, Rho S. Effects of nicotinamide supplementation in normal-tension glaucoma: a crossover placebo-controlled randomised clinical trial. British Journal of Ophthalmology. 2026;110(4):417-424. — PubMed PMID: 41167798
16. Giudiceandrea A, Cocuzza M, Gravina G, et al. Nicotinamide supplementation in glaucoma: a systematic review of human studies. Nutrients. 2026;18(17):2885. — PubMed PMID: 42739057
17. Schuhmann V, Küttel J, Van Eijgen J, Gugleta K, Hanssen H. Physical activity and exercise in primary open-angle glaucoma: a scoping review. Frontiers in Physiology. 2026;17:1834649. — PubMed PMID: 42528657

Historical Background

The term "glaucoma" derives from the ancient Greek word "glaukos," meaning blue-green, describing the appearance of the affected pupil. Richard Banister first linked elevated intraocular pressure to the disease in 1622. Albrecht von Graefe introduced iridectomy as a surgical treatment in 1856, and the modern era of glaucoma pharmacotherapy began with the introduction of timolol eye drops in 1978.

PubMed Topic Searches

1. Clinical trials on glaucoma — PubMed search
2. Systematic reviews of glaucoma — PubMed search
3. Meta-analyses on glaucoma — PubMed search
4. Treatment research on glaucoma — PubMed search
5. Mechanism studies of glaucoma — PubMed search
6. Epidemiology of glaucoma — PubMed search

Back to Table of Contents

Connections

• Ophthalmology
• Retinal Imaging — cup-to-disc and RNFL thinning explained
• Vision & the Retina — interactive animation
• Ginkgo Biloba
• Omega-3 Fatty Acids
• Macular Degeneration
• Cataracts
• Zinc
• Vitamin A
• Anti-Inflammatory Diet
• Vitamin C
• Vitamin E
• Magnesium
• Diabetes
• Oxidative Stress
• Hypertension
• Insulin Resistance
• Kale
• Blueberries
• Breathwork
• Uveitis and Eye Involvement
• Diabetic Retinopathy
• Dry Eye Disease
• Herbs covered on this site that discuss this condition: Coleus forskohlii (Forskolin) · Chrysanthemum (Chrysanthemum morifolium) · Saffron
• Bilberry

↑ Back to Table of Contents

×

Featured Videos